Featured Insight
Access90: Inflation Reduction Act Insights Series – Patient Affordability: A Key Question Answered
Will the Inflation Reduction Act actually increase drug affordability? Well…it’s complicated. RyanCox, VP, Director, PRECISIONvalue Access Experience Team, outlines the ways it will cut costs—and some watchouts. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insights Series – Impacts on Competition A Key Question Answered
How do you compete against a negotiated drug? As the Inflation Reduction Act challenges current formulary dynamics, PRECISIONvalue expert Erin Lopata has a succinct answer: Prove your value. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insight Series – Payer Controls: Question Two: How Could Manufacturers Adapt Their Approach to Patient Access?
Higher premiums. Increased brand exclusions. Limited treatment populations. Payers may deploy an arsenal of defenses against rising drug costs—and manufacturers should adapt to support patient access. Dominic Galante, Chief Medical Officer PRECISIONvalue, shares thoughts on effective strategies in this short Access90 video.
Access90: Inflation Reduction Act Insights Series – Patient Affordability: A Key Question Answered
Will the Inflation Reduction Act actually increase drug affordability? Well…it’s complicated. RyanCox, VP, Director, PRECISIONvalue Access Experience Team, outlines the ways it will cut costs—and some watchouts. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insights Series – Impacts on Competition A Key Question Answered
How do you compete against a negotiated drug? As the Inflation Reduction Act challenges current formulary dynamics, PRECISIONvalue expert Erin Lopata has a succinct answer: Prove your value. Learn more in this 90-second video.
Access90: Inflation Reduction Act Insight Series – Payer Controls: Question Two: How Could Manufacturers Adapt Their Approach to Patient Access?
Higher premiums. Increased brand exclusions. Limited treatment populations. Payers may deploy an arsenal of defenses against rising drug costs—and manufacturers should adapt to support patient access. Dominic Galante, Chief Medical Officer PRECISIONvalue, shares thoughts on effective strategies in this short Access90 video.
On-Demand Webinar – SDOH and EHR – How are EHR vendors enabling providers’ efforts to close care gaps attributable to SDOH?
In this 1 hour live webinar, Precision experts Thad Nowakowski, Tim Van Aken, and Maureen Hennessey discuss the role that Social Determinants of Health plays in contributing to care gaps, current or proposed quality measures to support health equity, and how the top EHR vendors are enabling end user’s efforts to both capture SDOH variables, and act upon them to close care gaps.
On-Demand Webinar – Trends in Oncology: US Payer Management Considerations for 2022 and Beyond
In the last five years, 83 novel oncology substances have launched - oncology PMPM spend is now the highest among medical benefit categories, with 105% growth anticipated by 2024. As these numbers suggest, oncology is a key area of focus for payers, who are willing to invest resources to support appropriate utilization, but who struggle to keep up with the rapidly evolving science.
On-Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
A Focus on the Inflation Reduction Act
Curious how the healthcare provisions in the Inflation Reduction Act will impact your business? Start with this booklet by key experts from PRECISIONvalue where 5 experts weigh in on how the Inflation Reduction Act will affect payers in addition to 2023 trends, events, and developments in the payer world. Download the booklet.
White Paper: Achieving Launch Excellence: A Novel Data- and Analytics-Informed Approach
Data and analytics can help drive and inform launch preparations and support efforts to achieve launch excellence through realistic goal-setting and risk mitigation. PRECISIONadvisors works with manufacturers, helping them make key decisions—related to product positioning, go-to-market strategy, and customer engagement across payers, providers, prescribers, and patients—through data- and analytics-driven insights. Learn how an integrated data-driven approach can set realistic goals and de-risk your launch.
White Paper: 2022 and Beyond: How Key Legislative Events Will Impact the Payer Landscape
Interested in learning more about several legislative events shaping the managed care landscape in 2022 and beyond? Check out this insightful white paper, based on our recent webinar, which features insights from PRECISIONvalue’s expert Access Experience Team on various legislative proposals and payers’ potential responses to regulatory changes.
Download Now: Precision October Events Calendar
The October Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
Download Now: Precision September Events Calendar
The October Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
Download Now: Precision June Events Calendar
The June Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
Collaboration is Needed Among Stakeholders for Genetic Tests to be Beneficial
More and more genetic tests are coming onto the market to help make sure the right patient gets the right drug at the right time. However, the sheer volume of these tests may be overwhelming payers in their coverage decisions. Precision’s Erin Lopata and others weigh in on the need for shareholders to work together to help establish the clinical utility that payers need to make coverage decisions on genetic tests.
40 Under 40: Isabella Sergio
We're excited to announce that two of our Precision colleagues have been named to MM+M's 40 Under 40 this year! Congratulations to Ashwin Athri, EVP, Managing Director, PRECISIONxtract, and Isabella Sergio, EVP, Managing Director, PRECISIONvalue. Now in its fourth year, 40 Under 40 honors the industry’s best-regarded young talent. We look forward to celebrating with Ashwin and Isabella, and all the other honorees, on February 16.
Social Determinants of Health (SDOH): Threee Trends to Watch in 2023
The healthcare sector is hastening adoption of population health approaches, including initiatives to improve outcomes by closing health disparity gaps. Precision's Maureen Hennessey, Ph.D., Jorge Font, Dominic Galante, M.D., Kris Kang, and Cynthia Miller, M.D. identify three trends to watch in 2023 to tackle pernicious social determinants of health challenges.
Early Access vs. Proven Efficacy: FDA’s Accelerated Approval Process
As Congress moves to improve the accelerated approval process through the Accelerated Approval Integrity Act, we must understand its history and ways to mitigate unnecessary spending while maintaining access to innovative treatments. Precision's Cynthia Miller warns of potential unintended consequences as Congress moves to improve the accelerated approval process.
On-Demand Webinar – Trends in Oncology: US Payer Management Considerations for 2022 and Beyond
In the last five years, 83 novel oncology substances have launched - oncology PMPM spend is now the highest among medical benefit categories, with 105% growth anticipated by 2024. As these numbers suggest, oncology is a key area of focus for payers, who are willing to invest resources to support appropriate utilization, but who struggle to keep up with the rapidly evolving science.
On-Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
Mitigating climate health isn’t just the physician’s job – It’s a job for everyone
Changes in climate and extreme weather affect every stakeholder in the healthcare system, not just the physicians on the front lines. Precision's Cynthia Miller suggests we need a patient focused strategy to manage environmental risk and offers solutions that align with incentives.
Hear From Key Stakeholders: The Future Treatment and Access Landscape for Cell & Gene Therapies Roundtable
Earlier this year, Precision Value & Health, in association with Precision ADVANCE, hosted an in-depth, live roundtable: The Future Treatment and Access Landscape for Cell and Gene Therapies
Download Now: Precision August Events Calendar
Don’t miss any of our upcoming Precision Value & Health events! Check out our monthly marketing activities calendar to stay ahead of upcoming dates!
Emerging Threats to Health Equity
While the pandemic exposed the nation’s enormous health disparities, it also led to significant policies that increased the number of insured Americans by expanding enrollment in Medicaid and Health Exchange plans. These advancements are at risk. Precision's Cynthia Miller and Maureen Hennessey discuss why discontinuing the policy changes will contribute to health inequities in myriad ways, and identify the essential role pharmaceutical companies can play in mitigating the impact.
MM+M Awards 2022 Finalist
We are honored to announce that PRECISIONvalue has been named as a finalist for the 2022 MM+M Awards in the Market Access Maven category! Congratulations to all finalists and thank you to our clients and team members for their roles in this impressive achievement.
Precision Drug Utilization Management: The Future of Oncology Medication Management
The exponential spending growth in oncology has resulted in myriad utilization management strategies by both payers and providers to control costs, especially drug costs. Precision's Julianna Kula, Bruce Edelen, Ronald Schleif, Jeffrey Becker, Mark Urban, and Elizabeth Oyekan explore current and emerging drug utilization management strategies being employed to help curtail oncology costs without adversely impacting patient quality and outcomes.
